Search Results

Executive strategic briefing examines how China’s evolving health policy, coverage, and financing environment is reshaping decisions across the medical technology lifecycle tags: #ChinaMarketAccess #LifeSciencesStrategy #PricingAndReimbursement #ChinaHealthPolicy #CommercialHealthInsurance

Gilead Sciences has picked up a new inflammatory disease program from China’s PepStar Therapeutics to pair with the Phase 2 inflammatory bowel disease asset emvistegrast.

China cracks down on some biotechnology ownership transfers—but will the new policy impact licensing deals?; Disc Medicine’s Phase 3 data sweep redeems rejected rare disease therapy, teeing up another FDA run; and the ESMO conference gets underway in Madrid this week, with much-anticipated data from Merck, and Summit Therapeutics.

China may be taking the majority of licensing deals this year but those transactions don’t tell the whole story, according to Locust Walk, which points to the spike in M&A among U.S. biotechs as leveling the playing field.

In this webinar, BioSpace will gathered experts to discuss China’s impact on the future of biotech and how both U.S. and Chinese companies can thrive—and maybe even collaborate.

Solstice Oncology, founded in February, is emerging from stealth having already secured an investigational new drug application from the FDA for a Phase 2 trial of a CTLA-4 antibody purchased from China’s Harbour BioMed.

While industry leaders are unsure whether the U.S. or China will prevail, they are largely united in the belief that Europe is lagging behind.

As geopolitical tensions between the U.S. and China grow increasingly complicated, here are five alternative territories for biotech investments.

The U.S. is scrambling to compete with a strategically positioned China on the biotech stage as the Asian country surpasses America in biomedical research and clinical trials. So far, China is winning.